Global Osteoarthritis Injectables Market Size study, by Injection Type (Hyaluronic Acid Injections, Corticosteroids Injections), by Anatomy (Knee Osteoarthritis, Hip Osteoarthritis), by End-use, and Regional Forecasts 2022-2032

The Global Osteoarthritis Injectables Market is valued approximately at USD 7.23 billion in 2023 and is anticipated to grow with a compound annual growth rate of more than 6.82% over the forecast period 2024–2032. As aging populations rise globally and the prevalence of joint-related disorders escalates, osteoarthritis has surfaced as a leading cause of disability and compromised quality of life. With an increasing number of patients turning away from invasive procedures, injectable therapies have garnered significant traction for offering targeted, non-surgical pain relief. These injectables, especially those based on corticosteroids and hyaluronic acid, are rapidly being adopted to alleviate joint inflammation and restore mobility—representing a crucial clinical tool in both acute flare-ups and long-term disease management.

The burgeoning demand is further fueled by the growing preference for minimally invasive interventions and outpatient settings. Hyaluronic acid injections, in particular, are gaining momentum due to their ability to restore the viscoelastic properties of synovial fluid, thereby enhancing joint lubrication and shock absorption. Meanwhile, corticosteroids are being employed to deliver potent anti-inflammatory effects, especially among patients with advanced degeneration. Innovations in formulation—such as extended-release injectables and novel delivery systems—are empowering physicians to tailor treatments based on anatomical sites, severity, and individual response, which in turn is fueling widespread clinical acceptance.

However, despite their growing popularity, the market encounters significant constraints. Concerns surrounding injection efficacy over time, adverse effects in long-term corticosteroid use, and inconsistent patient adherence due to repetitive injection schedules are curbing faster adoption. Furthermore, disparities in reimbursement policies and access to specialists—especially across developing nations—pose logistical and financial barriers to care. Nevertheless, opportunities abound in the form of pipeline product innovations, increased clinical trials assessing safety across patient subgroups, and strategic collaborations between device manufacturers and healthcare providers to broaden treatment access.

From an anatomical perspective, knee osteoarthritis remains the dominant contributor to injectable demand, primarily due to its higher incidence and the mechanical stress endured by the knee joint. Meanwhile, hip osteoarthritis is gradually catching up, driven by enhanced imaging techniques and early-stage diagnosis. The end-use landscape is transitioning as well—with hospitals and orthopedic clinics still leading—however, ambulatory surgical centers and specialty pain management centers are playing an increasingly pivotal role in delivering convenient and efficient care. Companies are strategically positioning their products across diverse end-user channels to maximize market penetration and establish brand preference.

Regionally, North America holds the lion’s share of the osteoarthritis injectables market, owing to its robust healthcare ecosystem, favorable reimbursement frameworks, and active engagement of leading manufacturers. Europe follows closely, with increased patient awareness and supportive regulatory pathways accelerating market growth. Meanwhile, Asia Pacific is poised for the fastest expansion through 2032. Factors such as rising geriatric populations, improving healthcare infrastructure, and growing demand for affordable, non-surgical treatments in countries like China, India, and Japan are expected to make this region a vital growth frontier in the coming years.

Major market player included in this report are:
• Bioventus Inc.
• Ferring Pharmaceuticals
• Zimmer Biomet Holdings, Inc.
• Seikagaku Corporation
• Anika Therapeutics, Inc.
• Sanofi S.A.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Fidia Farmaceutici S.p.A
• Mylan N.V.
• Chugai Pharmaceutical Co., Ltd.
• OrthogenRx Inc.
• Pfizer Inc.
• Novartis AG
• Flexion Therapeutics, Inc.

The detailed segments and sub-segment of the market are explained below:

By Injection Type
• Hyaluronic Acid Injections
• Corticosteroids Injections

By Anatomy
• Knee Osteoarthritis
• Hip Osteoarthritis

By End-use
• Hospitals
• Orthopedic Clinics
• Ambulatory Surgical Centers
• Others

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.